181. DNA Damage Response and Repair Genes and Anthracycline-Induced Cardiomyopathy in Childhood Cancer Survivors: A Report From the Children's Oncology Group and the Childhood Cancer Survivor Study.
作者: Xuexia Wang.;Purnima Singh.;Romina B Cejas.;Liting Zhou.;Noha Sharafeldin.;Patrick J Trainor.;Wendy Landier.;Changde Cheng.;Lindsey Hageman.;Fan Wang.;Yadav Sapkota.;Yutaka Yasui.;Melissa M Hudson.;Eric J Chow.;Saro H Armenian.;Joseph P Neglia.;Douglas S Hawkins.;Jill P Ginsberg.;Paul W Burridge.;Gregory T Armstrong.;Smita Bhatia.
来源: Circ Genom Precis Med. 2025年18卷2期e004813页
Anthracyclines induce cardiotoxicity via DNA double-strand breaks and reactive oxygen species formation, resulting in cardiomyocyte dysfunction. The role of DNA damage response/repair (DDR) genes in anthracycline-induced cardiomyopathy remains unstudied.
182. Clinical Features of Myocardial Infarction in Women With a History of Preeclampsia: A Population-Based Cohort Study.
作者: Neja Mudrovcic.;Elin Tegnesjö.;Rasmus Walter Green.;Maria Jonsson.;Christina Christersson.;Lina Bergman.;Karl Bergman.;Anna-Karin Wikström.;Susanne Hesselman.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷5期e011442页
Preeclampsia is associated with an increased lifetime risk of myocardial infarction. This study explored whether there is a difference in the clinical features and severity of myocardial infarction in women with previous preeclampsia compared with women with no history of preeclampsia.
183. Alcohol Exposure Among Patients With Dilated Cardiomyopathy and Their First-Degree Relatives: The DCM Precision Medicine Study.
作者: Javier Jimenez.;Hanyu Ni.;Stuart D Katz.;Garrie J Haas.;Jinwen Cao.;Muni Rubens.;Sandra Chaparro.;Anshul Saxena.;Mark Hofmeyer.;Evan Kransdorf.;Gregory A Ewald.;Alanna A Morris.;Anjali Owens.;Brian Lowes.;Douglas Stoller.;W H Wilson Tang.;Palak Shah.;Jane E Wilcox.;Frank Smart.;Jessica Wang.;Stephen S Gottlieb.;Daniel P Judge.;Jonathan O Mead.;Natalie Hurst.;Patricia K Parker.;Gordon S Huggins.;Elizabeth Jordan.;Daniel D Kinnamon.;Ray E Hershberger.; .
来源: Circ Genom Precis Med. 2025年18卷2期e004946页
Whether prolonged and excessive alcohol consumption contributes to dilated cardiomyopathy (DCM) remains uncertain. This study aimed to describe the prevalence of alcohol use in patients with DCM and their first-degree relatives (FDRs) and determine if cumulative alcohol exposure associates with DCM/partial DCM or modifies the association of DCM with DCM-relevant rare variants.
184. Evaluating Patient and Provider Experiences of Enrolling in a Remote Cardiovascular Health Program: A Qualitative Interview Study.
作者: Wesley Alexandra Spacht.;Simin Gharib Lee.;Matthew Varugheese.;Samantha Subramaniam.;Marian McPartlin.;Michela R Tucci.;Benjamin M Scirica.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷4期e010394页
Remote health management programs utilizing evidence-based algorithm-driven virtual care solutions for chronic disease management offer a novel approach to addressing implementation gaps for conditions such as hypertension. However, little is known about how to optimize patient enrollment.
185. Artificial Intelligence-Enhanced Analysis of Echocardiography-Based Radiomic Features for Myocardial Hypertrophy Detection and Etiology Differentiation.
作者: Inki Moon.;Jina Lee.;Seung-Ah Lee.;Dawun Jeong.;Jaeik Jeon.;Yeonggul Jang.;Sihyeon Jeong.;Jiyeon Kim.;Hong-Mi Choi.;In-Chang Hwang.;Youngtaek Hong.;Goo-Yeong Cho.;Yeonyee E Yoon.;Hyuk-Jae Chang.
来源: Circ Cardiovasc Imaging. 2025年18卷5期e017436页
While echocardiography is pivotal for detecting left ventricular hypertrophy (LVH), it struggles with etiology differentiation. To enhance LVH assessment, we aimed to develop an artificial intelligence algorithm using echocardiography-based radiomics. This algorithm is designed to detect LVH and differentiate its common etiologies, such as hypertrophic cardiomyopathy (HCM), cardiac amyloidosis (CA), and hypertensive heart disease (HHD), based on echocardiographic images.
186. Novel Protein-Based Biomarkers of Out-of-hospital Sudden Cardiac Death After Myocardial Infarction.
作者: Maomao Zhang.;Zhonghua Tong.;Naixin Wang.;Kaiyang Lin.;Yafei Zhang.;Dongni Wang.;Xiaoqi Wang.;Penghe Wang.;Qiannan Yang.;Yingjin Kong.;Mengdi Wang.;Jingxuan Cui.;Zhuozhong Wang.;Muhua Cao.;Lulu Li.;Ying Liu.;Zhaoying Li.;Shaohong Fang.;Fan Zhang.;Zhenwei Pan.;Jinwei Tian.;Bo Yu.
来源: Circ Arrhythm Electrophysiol. 2025年18卷4期e013217页
Early identification of out-of-hospital high-risk sudden cardiac death (SCD) after acute myocardial infarction is crucial for timely therapeutic interventions. However, left ventricular ejection fraction as a standalone clinical stratification tool has major limitations, necessitating improved risk stratification strategies.
187. One-Year Safety and Performance of a Dual-Chamber Leadless Pacemaker.
作者: Reinoud E Knops.;James E Ip.;Rahul Doshi.;Derek V Exner.;Pascal Defaye.;Robert Canby.;Maria Grazia Bongiorni.;Morio Shoda.;Gerhard Hindricks.;Petr Neužil.;Mayer Rashtian.;Karel T N Breeman.;Jordan R Nevo.;Leonard Ganz.;Chris Hubbard.;Anu Bulusu.;Vivek Y Reddy.
来源: Circ Arrhythm Electrophysiol. 2025年18卷4期e013619页
A dual-chamber leadless pacemaker can provide bradycardia therapy to most patients with pacemaker indications without the complications associated with a lead or pulse generator. We sought to confirm whether previously reported 3-month safety and performance outcomes were sustained through 12 months by determining whether 12-month complication-free and performance success rates exceeded their prespecified performance goals.
188. Transcarotid Versus Surgical Aortic Valve Replacement for the Treatment of Severe Aortic Stenosis.
作者: Juan Hernando Del Portillo.;Pedro Cepas-Guillén.;Dimitri Kalavrouziotis.;Eric Dumont.;Jean Porterie.;Jean-Michel Paradis.;Anthony Poulin.;Frederic Beaupré.;Marisa Avvedimento.;Silvia Mas-Peiro.;Siddhartha Mengi.;Siamak Mohammadi.;Josep Rodés-Cabau.
来源: Circ Cardiovasc Interv. 2025年18卷4期e014928页
Current guidelines recommend surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis and unfavorable iliofemoral access. Transcarotid transcatheter aortic valve replacement (TC-TAVR) has emerged as an alternative access in suboptimal transfemoral candidates, but no data exist comparing TC-TAVR and SAVR. The main objective of this study was to compare the clinical outcomes in a propensity-matched population of TC-TAVR and SAVR patients with severe aortic stenosis.
189. Predictive Value of Platelet FcγRIIa in Patients Treated With PCI Compared With Medical Therapy Alone After Myocardial Infarction.
作者: David J Schneider.;Sean R McMahon.;Dominick J Angiolillo.;Alexander C Fanaroff.;Homam Ibrahim.;Patrick K Hohl.;Brett L Wanamaker.;Mark B Effron.;Peter M DiBattiste.; .
来源: Circ Cardiovasc Interv. 2025年18卷4期e014939页
In patients with myocardial infarction (MI), quantifying platelet FcɣRIIa (pFCG) stratifies the risk of subsequent MI, stroke, and death. This report is a subgroup analysis of outcomes in patients treated with percutaneous coronary intervention (PCI) or medical management alone in an 800-patient, 25-center trial.
190. Blood Transfusion in Patients With Acute Myocardial Infarction, Anemia, and Heart Failure: Lessons From MINT.
作者: Andrew M Goldsweig.;William J Kostis.;Brandon M Herbert.;Claire Bouleti.;Brian J Potter.;Jordan B Strom.;Jocelyne Benatar.;Thao Huynh.;Srikanth Vallurupalli.;Estêvão Lanna Figueiredo.;J Dawn Abbott.;Howard A Cooper.;Andrew P DeFilippis.;Dean A Fergusson.;Shaun G Goodman.;Paul C Hébert.;Renato D Lopes.;Sunil V Rao.;Tabassome Simon.;Jeffrey L Carson.;Maria Mori Brooks.;John H Alexander.; .
来源: Circ Heart Fail. 2025年18卷4期e012495页
Blood transfusion may precipitate adverse outcomes, including heart failure (HF), among patients with acute myocardial infarction (MI). This study characterizes the effects of a restrictive or liberal transfusion strategy on outcomes in patients with MI and anemia with and without baseline HF.
191. XBP1s-EDEM2 Prevents the Onset and Development of HFpEF by Ameliorating Cardiac Lipotoxicity.
作者: Oveena Fonseka.;Rida Raja.;Claire Ross.;Sanskruti R Gare.;Jiayan Zhang.;Susanne S Hille.;Katharine King.;Andrea Ruiz-Velasco.;Namrita Kaur.;Xinyi Chen.;Jessica M Miller.;Riham R E Abouleisa.;Qinghui Ou.;Zhiyong Zou.;Xiangjun Zhao.;Cristian Sotomayor-Flores.;Derk Frank.;Eileithyia Swanton.;Martin R Pool.;Sara Missaglia.;Daniela Tavian.;Gabriele G Schiattarella.;Tao Wang.;Luigi Venetucci.;Christian Pinali.;Martin K Rutter.;Bernard D Keavney.;Elizabeth J Cartwright.;Tamer M A Mohamed.;Oliver J Müller.;Wei Liu.
来源: Circulation. 2025年151卷22期1583-1605页
Morbidity and mortality of heart failure with preserved ejection fraction (HFpEF) is increased in metabolic disorders. However, options for preventing and treating these prevalent outcomes are limited. Intramyocardial lipotoxicity contributes to cardiac dysfunction. Here, we investigate the mechanisms underlying EDEM2 (endoplasmic reticulum degradation-enhancing alpha-mannosidase-like protein 2) regulation of cardiac lipid homeostasis and assess strategies that inhibit the incidence and progression of HFpEF.
192. Hypertension and Atrial Fibrillation: A Frontier Review From the AF-SCREEN International Collaboration.
作者: Teemu J Niiranen.;Renate B Schnabel.;Aletta E Schutte.;Yitschak Biton.;Giuseppe Boriani.;Claire Buckley.;Alan C Cameron.;Albertino Damasceno.;Søren Z Diederichsen.;Wolfram Doehner.;Yutao Guo.;F D Richard Hobbs.;Boyoung Joung.;Graeme J Hankey.;Gregory Y H Lip.;Trudie Lobban.;Maja-Lisa Løchen.;Georges Mairesse.;Amam Mbakwem.;Peter A Noseworthy.;George Ntaios.;Steven Steinhubl.;George Stergiou.;Jesper Hastrup Svendsen.;Robert G Tieleman.;Jiguang Wang.;Neil R Poulter.;Jeff S Healey.;Ben Freedman.
来源: Circulation. 2025年151卷12期863-877页
Hypertension is the leading modifiable risk factor for atrial fibrillation (AF) and is estimated to be present in >70% of AF patients. This Frontiers Review was prepared by 29 expert members of the AF-SCREEN International Collaboration to summarize existing evidence and knowledge gaps on links between hypertension, AF, and their cardiovascular sequelae; simultaneous screening for hypertension and AF; and the prevention of AF through antihypertensive therapy. Hypertension and AF are inextricably connected. Both are easily diagnosed, often silent, and frequently treated inadequately. Together, they additively increase the risk of ischemic stroke, heart failure, and many types of dementia, resulting in greater all-cause mortality, considerable disease burden, and increased health care expenditures. Automated upper arm cuff blood pressure devices with implemented technology can be used to simultaneously detect both hypertension and AF. However, positive screening for AF with an oscillometric blood pressure monitor still requires ECG confirmation. The current evidence suggests that high-risk individuals aged ≥65 years or with treatment-resistant hypertension could benefit from AF screening. Since antihypertensive therapy effectively lowers AF risk, particularly in individuals with left ventricular dysfunction, hypertension should be the key target for AF prediction and prevention rather than merely a comorbidity of AF. Nevertheless, several important gaps in knowledge need to be filled over the next years, including the ideal method and selection of patients for simultaneous screening of hypertension and AF and the optimal antihypertensive drug class and blood pressure targets for AF prevention.
193. Improving Cardiovascular Health Through the Consideration of Social Factors in Genetics and Genomics Research: A Scientific Statement From the American Heart Association.
作者: Shakira F Suglia.;Bertha Hidalgo.;Andrea A Baccarelli.;Andres Cardenas.;Scott Damrauer.;Amber Johnson.;Kaitlin Key.;Mingyu Liang.;Jared W Magnani.;Brittany Pate.;Mario Sims.;Gabriel S Tajeu.; .
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷5期e000138页
Cardiovascular health (CVH) is affected by genetic, social, and genomic factors across the life course, yet little research has focused on the interrelationships among them. An extensive body of work has documented the impact of social determinants of health at both the structural and individual levels on CVH, highlighting pathways in which racism, housing, violence, and neighborhood environments adversely affect CVH and contribute to disparities in cardiovascular disease. Genetic factors have also been identified as contributors to risk for cardiovascular disease. Emerging evidence suggests that social factors can interact with genetic susceptibility to affect disease risk. Increasingly, social factors have been shown to affect epigenetic markers such as DNA methylation, which can regulate gene and protein expression. This is a potential biological mechanism through which exposure to poor social determinants of health becomes physically embodied at the molecular level, potentially contributing to the development of suboptimal CVH and chronic disease, thus reinforcing and propagating health disparities. The objective of this statement is to highlight and summarize key literature that has examined the joint associations between social, genetic, and genomic factors and CVH and cardiovascular disease.
194. Determinants and Prognostic Value of Early Gadolinium Enhancement-Derived Myocardial Salvage Index in STEMI.
作者: Jin-Yi Xiang.;Jin-Yu Zheng.;Yi-Si Dai.;Ling-Yi Yu.;Yu-Fan Qian.;Wei-Hui Xie.;Ruo-Yang Shi.;Bing-Hua Chen.;Jun Pu.;Lian-Ming Wu.
来源: Circ Cardiovasc Imaging. 2025年18卷4期e017830页
T2-weighted imaging is commonly used to measure myocardial salvage in reperfused myocardial infarction but is hindered by poor reproducibility and indistinct boundaries. Early gadolinium enhancement (EGE) emerges as an alternative for measuring the area at risk. This study aims to evaluate the determinants of the myocardial salvage index (MSI) derived from EGE and its prognostic implications.
195. Effects of Nicorandil, Isosorbide Mononitrate, or Diltiazem on Radial Artery Grafts After CABG: The Randomized ASRAB-Pilot Trial.
作者: Yunpeng Zhu.;Wei Zhang.;Kaijie Qin.;Yun Liu.;Haoyi Yao.;Zhe Wang.;Xiaofeng Ye.;Mi Zhou.;Haiqing Li.;Jiapei Qiu.;Hong Xu.;Yanjun Sun.;Mario Gaudino.;Qiang Zhao.
来源: Circ Cardiovasc Interv. 2025年18卷4期e014542页
The optimal antispastic treatment after coronary artery bypass grafting using radial artery (RA) grafts is controversial. This clinical trial aimed to generate pilot comparative data on the effects of nicorandil, isosorbide mononitrate, or diltiazem on RA grafts.
196. How to Improve Radiation Protection in Interventional Cardiology Procedures.
作者: Dimitrios Strepkos.;Athanasios Rempakos.;Michaella Alexandrou.;Deniz Mutlu.;Pedro E P Carvalho.;Ali Bahbah.;Ryan D Madder.;Simon R Dixon.;Anastasios Milkas.;Kevin J Croce.;William J Nicholson.;Lorenzo Azzalini.;Bavana V Rangan.;Olga C Mastrodemos.;Konstantinos Voudris.;Ahmed Al-Ogaili.;M Nicholas Burke.;Yader Sandoval.;Emmanouil S Brilakis.
来源: Circ Cardiovasc Interv. 2025年18卷4期e014808页
The use of ionizing radiation during cardiac catheterization procedures poses risks to patients and medical staff, both directly and indirectly through orthopedic injuries caused by lead aprons. In this review, we summarize recent advances in radiation protection in the cardiac catheterization laboratory and discuss the effectiveness of traditional and novel radiation protection strategies and equipment.
197. Enhancing Stroke Awareness and Activation Among High-Risk Populations: A Randomized Direct Mail Intervention in Diverse Healthcare Settings.
作者: Christine C Groves.;Teresa M Damush.;Laura J Myers.;Fitsum Baye.;Joanne K Daggy.;Anthony J Perkins.;Holly Martin.;Layne Mounsey.;Daniel O Clark.;Linda S Williams.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷5期e011425页
Many patients are unaware of their stroke risk. The purpose of this research was to compare the effect of behaviorally tailored mailed messages on patient activation to reduce stroke risk.
198. Natural History and Clinical Outcomes of Patients With DSG2/DSC2 Variant-Related Arrhythmogenic Right Ventricular Cardiomyopathy.
作者: Liang Chen.;Yuxiao Hu.;Ardan M Saguner.;Barbara Bauce.;Yaxin Liu.;Anteng Shi.;Fu Guan.;Zhongli Chen.;Maria Bueno Marinas.;Lingmin Wu.;Deborah Foltran.;Alexis Hermida.;Veronique Fressart.;Serena Pinci.;Rudy Celeghin.;Zixian Chen.;Baowei Zhang.;Yubi Lin.;Xiaorui Liu.;Marco Cason.;Marika Martini.;Ilaria Rigato.;Corinna Brunckhorst.;Ruth Biller.;Cristina Basso.;Bing Yang.;Xiaoyan Zhao.;Julia Cadrin-Tourigny.;Alessio Gasperetti.;Cynthia A James.;Xianliang Zhou.;Estelle Gandjbakhch.;Kalliopi Pilichou.;Firat Duru.;Shengshou Hu.
来源: Circulation. 2025年151卷17期1213-1230页
Genetic variants in desmosomal cadherins, desmoglein 2 (DSG2) and desmocollin 2 (DSC2), cause a distinct form of arrhythmogenic right ventricular cardiomyopathy (ARVC), which remains poorly reported. In this study, we aimed to provide a comprehensive description of the phenotypic expression, natural history, and clinical outcomes of patients with this ARVC subset.
199. 3D Echocardiographic and CMR Imaging for the Assessment of Right Ventricular Function and Tricuspid Regurgitation Severity.
作者: Philipp M Doldi.;Ludwig T Weckbach.;Nicola Fink.;Lukas Stolz.;Cecilia Ennin.;Julien Dinkel.;Philipp Lurz.;Holger Thiele.;Rebecca T Hahn.;João L Cavalcante.;Christian Besler.;Jörg Hausleiter.
来源: Circ Cardiovasc Imaging. 2025年18卷4期e017638页
Tricuspid regurgitation (TR) is associated with increased mortality and is often underdiagnosed due to limitations in imaging modalities. While routine 2-dimensional echocardiography (2DE) demonstrates frequent disagreement with cardiac magnetic resonance imaging (CMR) in classifying TR severity, the incremental value of 3-dimensional echocardiography (3DE) remains unknown also due to the lack of a generalizable grading scheme across imaging modalities. Therefore, this study provides an intermodality comparison of all 3 imaging modalities (2DE, 3DE, and CMR) in evaluating TR severity and proposes an adapted 5-class grading scheme for TR severity using CMR.
200. Severe Mitral Regurgitation in Paradoxical Low-Flow, Low-Gradient Severe Aortic Stenosis.
作者: Shani Dahan.;Jacob P Dal-Bianco.;Ygal Plakht.;Mayooran Namasivayam.;Romain Capoulade.;Xin Zeng.;Jonathan Passeri.;Evin Yucel.;Michael H Picard.;Robert A Levine.;Judy Hung.
来源: Circ Cardiovasc Imaging. 2025年18卷5期e017598页
Patients with paradoxical low-flow, low-gradient severe aortic stenosis exhibit low transvalvular flow rate (Q), while maintaining preserved left ventricular ejection fraction. Severe mitral regurgitation (MR) also causes a low-flow state, adding complexity to diagnosis and management. This study aimed to examine the impact of severe MR on outcomes in paradoxical low-flow, low-gradient severe aortic stenosis.
|